Elacytarabine has single-agent activity in patients 
with advanced acute myeloid leukaemia

Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

(2012) F J Giles et al.   LEUKEMIA

Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

(2012) Francis Giles et al.   LEUKEMIA RESEARCH

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

(2011) Pamela S. Becker et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

(2011) Jorge Cortes et al.   CANCER

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

(2011) Auke D. Adema et al.   INVESTIGATIONAL NEW DRUGS

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience

(2010) Holbrook E. Kohrt et al.   AMERICAN JOURNAL OF HEMATOLOGY

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

(2010) Gautam Borthakur et al.   LEUKEMIA & LYMPHOMA

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902

(2010) Richard M. Stone et al.   LEUKEMIA RESEARCH

The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues

(2010) Marit Liland Sandvold et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells

(2010) A. D. Adema et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression

(2009) Guilan Jin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group

(2009) Mark R. Litzow et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

(2009) A. E. Perl et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia

(2009) Aaron D. Schimmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia

(2009) Marco Montillo et al.   LEUKEMIA RESEARCH

Human Nucleoside Transporters: Biomarkers for Response to Nucleoside Drugs

(2009) Vijaya L. Damaraju et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

(2008) Svein Dueland et al.   ACTA ONCOLOGICA

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

(2008) T. Qin et al.   BLOOD

CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines

(2008) Carlos M. Galmarini et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+Primary Resistant or Relapsed Acute Myeloid Leukemia

(2008) Patrice Chevallier et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

(2008) David J. Adams et al.   LEUKEMIA & LYMPHOMA

Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia

(2007) Paula Fernández Calotti et al.   BIOCHEMICAL PHARMACOLOGY